Hikma Pharmaceuticals (HIK) Share Price, News & Analysis

Company Overview

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: 1,918 to 1,959.13
• 50-Day Range: 1,772 to 2,002
• 52-Week Range: 1,750 to 2,165
• Volume: 898,500 shs
• Average Volume: 503,719 shs
• Market Capitalization: £4.33 billion
• P/E Ratio: 3,004.62
• Dividend Yield: 3.17%
• Price Target: GBX 2,383.33
• Consensus Rating: Moderate Buy

Hikma Pharmaceuticals Stock Analysis - MarketRank™

Hikma Pharmaceuticals scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Hikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Hikma Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hikma Pharmaceuticals is 3,004.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 113.42.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hikma Pharmaceuticals is 3,004.62, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 90.05.

Price to Earnings Growth Ratio

Hikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Hikma Pharmaceuticals has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HIK.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Hikma Pharmaceuticals pays a meaningful dividend of 3.25%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Hikma Pharmaceuticals does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Hikma Pharmaceuticals is 9,538.46%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -2.61

Short Interest

There is no current short interest data available for HIK.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

Hikma Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Hikma Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.54% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.09% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HIK Stock Analysis - Frequently Asked Questions

How have HIK shares performed this year?

Hikma Pharmaceuticals' stock was trading at GBX 1,789 at the beginning of the year. Since then, HIK stock has increased by 9.2% and is now trading at GBX 1,953.
View the best growth stocks for 2024 here.

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: LON:HIK
• CUSIP: N/A
• CIK: N/A
• Web: www.hikma.com
• Phone: +44-20-73992760
• Fax: N/A
• Employees: 9,100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 2,383.33
• High Stock Price Target: GBX 2,750
• Low Stock Price Target: GBX 2,000
• Potential Upside/Downside: +22.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.65
• Trailing P/E Ratio: 3,004.62
• Forward P/E Ratio: 12.80
• P/E Growth: 2.38
• Net Income: £285 million
• Net Margins: 9.45%
• Pretax Margin: N/A
• Return on Equity: 12.88%
• Return on Assets: 9.40%

Debt

• Debt-to-Equity Ratio: 55.48
• Current Ratio: 1.66
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: £3.02 billion
• Price / Sales: 1.43
• Cash Flow: GBX 234.20 per share
• Price / Cash Flow: 8.34
• Book Value: GBX 1,031 per share
• Price / Book: 1.89

Miscellaneous

• Outstanding Shares: 221,880,000
• Free Float: N/A
• Market Cap: £4.33 billion
• Optionable: Not Optionable
• Beta: 0.41